Tazemetostat is the first EZH2 inhibitor approved by the FDA; however, its indications are for patients aged 16 years and older with epithelioid sarcoma or relapsed/refractory EZH2-mutated follicular lymphoma [21]. This evidence concerns the gene EZH2 and follicular lymphoma.